Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation

Journal of Clinical Virology

Volumn 54, Issue 2, 2012, Pages 125-129

  Emery, Vincent C ^a   Asher, Kevin ^b   Sanjuan, Cristina de Juan ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Audit; Immunocompromised host; Transplantation

Indexed keywords

VALGANCICLOVIR;

ARTICLE; CYTOMEGALOVIRUS INFECTION; FOLLOW UP; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOM; UNITED KINGDOM;

ADULT; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GREAT BRITAIN; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDIES;

EID: 84860351506     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.02.020     Document Type: Article

References (20)

1. Fishman J.A., Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 1998, 338(24):1741.
2. Fisher R.A. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl Infect Dis 2009, 11(3):195.
3. Ekberg H., Tedesco-Silva H., Demirbas A., Vítko S., Nashan B., Gürkan A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357(25):2562.
4. Ekberg H., van G.T., Kaplan B., Bernasconi C. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. Transplantation 2011, 92(1):82.
5. Hodson E.M., Craig J.C., Strippoli G.F., Webster A.C. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008, (2):CD003774.
6. Hodson E.M., Jones C.A., Webster A.C., Strippoli G.F., Barclay P.G., Kable K., et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005, 365(9477):2105.
7. Paya C., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004, 4(4):611.
8. Humar A., Lebranchu Y., Vincenti F., Blumberg E.A., Punch J.D., Limaye A.P., et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010, 10(5):1228.
9. Kliem V., Fricke L., Wollbrink T., Burg M., Radermacher J., Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008, 8(5):975.
10. Khoury J.A., Storch G.A., Bohl D.L., Schuessler R.M., Torrence S.M., Lockwood M., et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006, 6(9):2134.
11. Kotton C.N., Kumar D., Caliendo A.M., Asberg A., Chou S., Snydman D.R., et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010, 89(7):779. Transplantation Society International CMV Consensus Group.
12. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34(8):1094.
13. Freeman R.B., Paya C., Pescovitz M.D., Humar A., Dominguez E., Washburn K., et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004, 78(12):1765.
14. Humar A., Mazzulli T., Moussa G., Razonable R.R., Paya C.V., Pescovitz M.D., et al. Clinical utilityof cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplantrecipients. Am J Transplant 2005, 5(5):1065. Valganciclovir Solid Organ Transplant Study Group.
15. Kumar D., Chernenko S., Moussa G., Cobos I., Manuel O., Preiksaitis J., et al. Cell-mediated immunity to predict cytomegalovirus disease inhigh-risk solid organ transplant recipients. Am J Transplant 2009, 9(5):1214.
16. Emery V.C., Cope A.V., Bowen E.F., Gor D., Griffiths P.D. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999, 190(2):177.
17. Emery V.C., Sabin C.A., Cope A.V., Gor D., Hassan-Walker A.F., Griffiths P.D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355(9220):2032.
18. Humar A., Paya C., Pescovitz M.D., Dominguez E., Washburn K., Blumberg E., et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 2004, 4(4):644.
19. Boillat B.N., Pascual M., Venetz J.P., Nseir G., Meylan P.R., Manuel O. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Transplantation 2011, 91(2):251.
20. McGillicuddy J.W., Weimert N.A., Taber D.J., Turner A., Mitchell L.A., Wray D.W., et al. Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk?. Transplantation 2010, 89(10):1218.